These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 35004667)

  • 1. Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression.
    Cheng JN; Yuan YX; Zhu B; Jia Q
    Front Cell Dev Biol; 2021; 9():740827. PubMed ID: 35004667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer.
    Li L; Li M; Jia Q
    Pathol Res Pract; 2023 Aug; 248():154711. PubMed ID: 37494802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
    Law AMK; Valdes-Mora F; Gallego-Ortega D
    Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression.
    Yin K; Xia X; Rui K; Wang T; Wang S
    Front Oncol; 2020; 10():610104. PubMed ID: 33384962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy.
    Bullock K; Richmond A
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.
    Wilkerson A; Kim J; Huang AY; Zhang M
    Curr Top Med Chem; 2017; 17(16):1843-1857. PubMed ID: 27875974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
    Weber R; Fleming V; Hu X; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():1310. PubMed ID: 29942309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.
    Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH
    J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
    Toor SM; Elkord E
    Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
    Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.
    Mabuchi S; Sasano T; Komura N
    Cells; 2021 Feb; 10(2):. PubMed ID: 33562495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
    De Veirman K; Van Valckenborgh E; Lahmar Q; Geeraerts X; De Bruyne E; Menu E; Van Riet I; Vanderkerken K; Van Ginderachter JA
    Front Oncol; 2014; 4():349. PubMed ID: 25538893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.